Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Chronic Cough Trials

<< Previous

Bullboard Posts

Next >>

Post by nodaytraderon Jan 11, 2023 8:49pm

207 Views

Post# 35217299

Chronic Cough Trials

In response to recent comments:

1. Christopher Moreau has stated that AGN's chronic cough study will mirror the Merck and Bellus studies so that direct comparisons can be made.
2. The study will include participants in the USA - presumably the new medical board advisor can help with that.
3. Both Merck and Bellus are quoted on NASDAQ. AGN is not.
If AGN were valued on the same basis as Bellus ($1.25 billion), its share price would be over $500.

<< Previous

Bullboard Posts

Next >>

Unlocking potential in TAG Oil’s Badr Oilfield Abu-Roash 'F' project